Introduction
Gene therapy provides a means of addressing protein deficiencies or excesses that contribute to diseases. There are several types of ocular diseases that can be treated by gene transfer, and the eye has characteristics that are potentially advantageous. It is a small compartment, which can decrease the amount of virus needed and enhance transduction efficiency. One important application is gene replacement for mutated genes that code for proteins needed for the normal functioning of photoreceptors or retinal pigmented epithelial (RPE) cells. [1] [2] [3] [4] Gene transfer provides a way to replace the defective gene product and potentially prevent retinal degeneration. Another application is to transduce cells within the eye to produce a survival factor, resulting in a high intraocular level of the survival factor in an attempt to rescue photoreceptors from mutation-induced cell death. [5] [6] [7] [8] A third application is to transduce intraocular cells to produce an antiangiogenic protein to suppress ocular neovascularization. [9] [10] [11] [12] [13] [14] There is great potential for each of these gene therapy applications, but there are also theoretical pitfalls. Two areas of concern are the possibility of vector-related toxicity and uncertainties associated with prolonged transgene expression. Adenoviral (Ad) vectors have several advantages, such as relative ease of production, their ability to accept large gene cassettes, and transduction of a variety of noncycling cells resulting in high expression levels. However, Ad vectors induce an immune response that results in inflammation and mediates destruction of transduced cells. Fortunately, there is little transduction of retinal neurons by Ad vectors, but there is still the possibility of bystander damage. [15] [16] [17] Adeno-associated viral (AAV) vectors and lentivirus vectors induce little immune response and mediate long-term expression. [18] [19] [20] [21] [22] [23] On the one hand, this is an advantage, but on the other the effects of excessive and/or prolonged expression of various transgenes in retinal cells are unknown. Both AAV and HIV vectors transduce photoreceptors and transduction of photoreceptors may be particularly risky, because even increased expression of wild-type rhodopsin or peripherin/rds can result in degeneration of photoreceptors. 24, 25 For gene replacement for loss of function photoreceptor mutations, transduction of photoreceptors is unavoidable, and may require inducible promoter systems that provide precise control of transgene expression. For the other applications, the particular cells transduced are irrelevant provided sufficient transgene product reaches needed locations within the eye. Targeting of cells that are not critical for visual function is a prudent approach. One way to do this is to perform periocular injections of vector to transduce connective tissue cells on the outside of the eye. In this study, we tested the feasibility of using this approach to treat ocular neovascularization with AdPEDF.11.
Materials and methods

Adenoviral vectors expressing b-galactosidase or PEDF
Production and quantification of type 5 adenoviral vectors that express b-galactosidase or human PEDF from a cytomegalovirus (CMV) immediate early promoter expression cassette have been previously described. 10, 17, 26 The vectors were deleted for E1A, E1B, E3 and either contain the intact E4 region (AdLacZ.10) or are deleted for the E4 region (AdPEDF.11). A vector that does not express transgene product (AdNull.11) was used as a control.
Periocular injection of vectors or PEDF protein
Mice were treated humanely in strict compliance with the Association for Research in Vision and Ophthalmology statement on the use of animals in research. Recombinant PEDF was produced and purified as previously described. 10 Adult or neonatal C57BL/6 or Balb/C mice were anesthetized and a 32 gauge needle of a Hamilton syringe was inserted under the conjunctiva of one eye and 3 ml containing 5 Â 10 9 AdLacZ.10 was injected. Mice were euthanized at 1, 4, or 14 days after injection. Periocular injections of AdPEDF.11 or AdNull.11 were carried out in untreated adult C57BL/6 mice immediately after laser-induced rupture of Bruch's membrane, or in neonatal mice with oxygen-induced ischemic retinopathy on day 3 of oxygen treatment, postnatal day (P) 10. Recombinant PEDF protein 10 was dissolved at a concentration of 0.6 mg/ml in buffer containing 150 mM sodium chloride and 20 mM sodium phosphate, pH 7.4. Adult C57BL/6 mice were given an injection of 5 ml containing 3 mg of PEDF under the conjunctiva of one eye. The mice were euthanized 2, 6, and 24 h after injection and ocular frozen sections were immunohistochemically stained for PEDF as described below.
Assessment of LacZ expression
At the 4 day time point, ocular and orbital sections were stained for LacZ, and at all three time points liver sections were stained for LacZ. Eyes, orbital tissue, or liver were frozen in optimal cutting temperature embedding compound (OCT; Miles Diagnostics, Elkhart, IN, USA). Frozen section of (10 mm) were rinsed in PBS and reacted overnight with 1 mg/ml of X-gal (5-bromo-4-chloro-3-indolyl galactopyranoside, Sigma) in a solution containing 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 Á 3H 2 O, 1 mM MgCl 2 in PBS. Sections were postfixed for 15 min in 0.5% glutaraldehyde in PBS and washed in PBS.
Assessment of PEDF expression
Expression of PEDF was assessed by immunohistochemistry or enzyme-linked immunoabsorbant assay (ELISA). Four days after periocular injection of AdPEDF.11 or AdNull.11, mice were killed and tissues were dissected, snap-frozen in liquid nitrogen, and stored at À801C for ELISA or eyes were frozen in OCT. Immunohistochemical staining for PEDF was done using a previously characterized rabbit anti-human PEDF antibody by a described technique. 10 Briefly, 10 mm frozen sections were fixed with 4% paraformaldehyde for 30 min, washed with 0.05 M Tris-buffered saline (TBS), incubated in methanol/H 2 O 2 for 10 min at 41C, and washed with TBS. Specimens were blocked with 10% normal goat serum (NGS) in 0.05 M TBS for 30 min at room temperature to prevent nonspecific binding. The slides were incubated with a 1 : 50 dilution of rabbit antihuman PEDF antibody in 1% NGS/0.05 M TBS overnight at 41C in a humidified chamber. After warming to room temperature, the sections were washed with 1% NGS/ 0.05 M TBS and incubated with biotinylated goat antirabbit antibody for 30 min. After washing, the slides were incubated in streptavidin-phosphatase and developed with HistoMark Red (Kirkegaard and Perry, Gaithersburg, MD, USA) according to the manufacturer's instructions. Sections were dehydrated and mounted with Cytoseal. For controls, anti-PEDF antibody was incubated for 3 h at room temperature with a five-fold molar excess of PEDF prior to incubation on tissue sections.
For ELISAs, specimens were mechanically homogenized with mortar and pestle, sonicated in PBS/100 mM PMSF using a Branson 2510 sonicator (Branson, Danbury, CT, USA), and microfuged. Total protein was measured in supernatants using the Bio-Rad Protein Assay (BioRad, Hercules, CA, USA) and concentrations of PEDF were measured using a two antibody sandwich ELISA in 96-well immunoplates (Immulon-IV, Dynatech). Each well was coated with 100 ml of 0.1 M NaHCO 3 containing 2 mg/ml of a mouse monoclonal anti-human PEDF antibody (Chemicon, Temecula, CA, USA) for 16 h at 41C. The plates were washed 3 times with PBS/0.05% Tween-20 and blocked for 1 h at 371C with 200 ml of PBS/ 10% FBS. After washing, tissue samples or recombinant human PEDF 27 standards (1-1000 ng/ml) were added. After 1.5 h at room temperature, plates were washed and then incubated for 1 h at room temperature with 100 ml of rabbit anti-human PEDF polyclonal antibody conjugated to horseradish peroxidase (0.5 mg/ml in PBS/10% FBS). The wells were washed and a TMB substrate/peroxide mixture was added for 25 min. The reaction was stopped with 100 ml of 0.5 M sulfuric acid and the plate was read with a microplate reader. The limit of sensitivity of the assay was 0.1 ng/ml.
Mouse model of laser-induced choroidal neovascularization
Mice were anesthetized with ketamine hydrochloride (100 mg/kg body weight), pupils were dilated with 1% tropicamide, and diode laser photocoagulation was used to rupture Bruch's membrane at three locations in each eye of each mouse as previously described. 28 Briefly, laser photocoagulation (75 mm spot size, 0.1 s duration, 120 mW) was delivered using the slit-lamp delivery system and a hand-held cover slide as a contact lens. Burns were performed in the 9, 12, and 3 o'clock positions 2-3 disk diameters from the optic nerve. Production of a vaporization bubble at the time of laser, which indicates rupture of Bruch's membrane, is an Periocular injection of AdPEDF vectors P Gehlbach et al important factor in obtaining CNV, 28 so only burns in which a bubble was produced were included in the study. After photocoagulation treatment, one eye was given a periocular injection of 5 Â 10 9 or 1 Â 10 9 particles of AdPEDF.11 and the other eye was given a periocular injection of 5 Â 10 9 particles of AdNull.11 or no injection. After 2 weeks, mice were killed and the amount of choroidal neovascularization was assessed.
Measurement of the sizes of laser-induced CNV lesions
Two weeks after laser treatment, the sizes of CNV lesions were measured in choroidal flat mounts. 29 Mice used for the flat mount technique were anesthetized and perfused with 1 ml of phosphate-buffered saline containing 50 mg/ml of fluorescein-labeled dextran (2 Â 10 6 average MW, Sigma, St Louis, MO, USA) as previously described. 30 The eyes were removed and fixed overnight in 10% phosphate-buffered formalin. The cornea and lens were removed and the entire retina was carefully dissected from the eyecup. Radial cuts (4-7, average 5) were made from the edge to the equator and the eyecup was flat mounted in Aquamount with the sclera facing down. Flat mounts were examined by fluorescence microscopy on an Axioskop microscope (Zeiss, Thornwood, NY, USA) and images were digitized using a three color CCD video camera (IK-TU40A, Toshiba, Tokyo, Japan) and a frame grabber. Image-Pro Plus software (Media Cybernetics, Silver Spring, MD, USA) was used to measure the total area of hyperfluorescence associated with each burn, corresponding to the total fibrovascular scar.
Mouse model of oxygen-induced ischemic retinopathy
Ischemic retinopathy was produced in C57BL/6 mice by a method described by Smith et al. 31 Seven-day-old (P7) mice and their mothers were placed in an airtight incubator and exposed to an atmosphere of 7573% oxygen for 5 days. Incubator temperature was maintained at 23721C, and oxygen was continuously monitored with a PROOX model 110 oxygen controller (Reming Bioinstruments Co., Redfield, NY, USA). At P10, mice were given a periocular injection of 5 Â 10 9 particles AdPEDF.11 in one eye and 5 Â 10 9 particles of AdNull.11 or no injection in the other eye. After injection, the mice were returned to oxygen for two more days and then put in room air. At P17, the mice were killed, and eyes were rapidly removed and frozen in OCT embedding compound.
Quantitation of retinal neovascularization
Frozen sections (10 mm) of eyes from injected and uninjected mice were histochemically stained with biotinylated Griffonia simplicifolia lectin B4 (GSA, Vector Laboratories, Burlingame, CA, USA), which selectively binds to vascular cells. Slides were incubated in methanol/H 2 O 2 for 10 min at 41C, washed with 0.05 M Tris-buffered saline, pH 7.6 (TBS), and incubated for 30 min in 10% normal porcine serum. Slides were incubated for 2 h at room temperature with biotinylated GSA, and after rinsing with 0.05 M TBS they were incubated with avidin coupled to peroxidase (Vector Laboratories) for 45 min at room temperature. After being washed for 10 min with 0.05 M TBS, slides were incubated with diaminobenzidine (Research Genetics, Huntsville, AL, USA), to give a brown reaction product. Some slides were counterstained with eosin, and all were mounted with Cytoseal (Stephens Scientific, Riverdale, NJ, USA).
To perform quantitative assessments, 10 mm serial sections were cut through the entire eye starting with sections that included the iris root on one side of the eye and proceeding to the iris root on the other side. Every 10th section, roughly 100 mm apart, was stained with GSA, examined with an Axioskop microscope, and images were digitized using a three CCD color video camera and a frame grabber. Image-Pro Plus software was used to delineate GSA-stained cells on the surface of the retina and their area was measured. For plotting the area measurements for the figure, the mean of the measurements from each eye was used as a single experimental value.
Statistical analysis
In mice with laser-induced rupture of Bruch's membrane or ischemic retinopathy, the effect of periocular injection of AdPEDF.11 on the amount of neovascularization was evaluated. For the laser-induced choroidal neovascularization model, the analysis included up to three neovascularization area measurements per eye. Some eyes had less than three, because whenever the laser was not associated with the formation of a bubble, that particular lesion was excluded. All measurements from either eye of a mouse were assumed to be exchangeable when modeling correlation structure, and were assumed to be subject to nonerror variability due only to treatment for experiments in which different treatments were administered to each eye of a mouse. We have previously demonstrated that this assumption is valid. 32 An overall test for treatment effect was first performed using analysis of variance (ANOVA). If the overall test indicated a significant treatment effect, individual treatments were compared with null vector injection using analyses that adjusted for multiple comparisons including Tukey's test, Bonferroni (Dunn) test, and the general linear model (GLM) with Dunnett's test. The level established for statistical significance was a P-value o0.05 (two-tailed test). All analyses were performed using SAS software (SAS Institute, Inc., Cary, NC, USA).
Results
Periocular injection of AdLacZ.10 results in prominent LacZ expression around the eye Four days after periocular injection of 5 Â 10 9 particles of AdLacZ.10, there was prominent staining for LacZ in the lateral rectus muscle (asterisks), orbital fat and the connective tissue around the site of injection ( Figure  1a ). There was little or no staining in other quadrants of the orbit, but staining of the sclera and episclera often extended all the way around the globe (arrow). Occasionally, sections adjacent to the site of injection in which there was strong staining of periorbital tissue also showed faint staining of retinal cells (Figure 1b , arrowheads), indicating that a small amount of vector had penetrated the sclera. The frequent staining of episclera in the absence of other periocular tissues in areas remote from the injection site (Figure 1c, arrow) suggests a tissue plane between Tenon's capsule and episclera that Periocular injection of AdPEDF vectors P Gehlbach et al facilitates spread of virus and a differential adenoviral tropism for episcleral tissue. Even when there was intense staining of surrounding periocular tissue, there was no staining in the optic nerve, suggesting that the optic nerve sheath prevented viral penetration ( Figure  1d ). Blue staining was observed in the lacrimal gland in orbits injected with virus ( Figure 1e, panel 1) , in the contralateral orbits (panel 3), and in uninjected mice (panel 2), suggesting some sort of endogenous bgalactosidase-like activity, rather than viral transduction. High magnification views showed intense LacZ staining in muscle fibers (Figure 1f, asterisk) and the episclera (arrow). Other than the lacrimal gland, there was no staining of periocular tissue in orbits contralateral to vector injection (Figure 1g-i) . There was no staining in liver sections 1 day after injection (Figure 1j ), but 4 days after injection each liver evaluated showed a few LacZpositive cells (Figure 1k ). At 14 days after injection, staining was no longer detected in the liver (Figure 1l ).
Periocular injection of AdPEDF.11 results in localization of PEDF in periocular and intraocular tissues
Four days after periocular injection of 5 Â 10 9 particles of AdPEDF.11, there was immunohistochemical staining for PEDF in the retina, periocular tissue, and optic nerve (Figure 1m and p) . Staining within the retina and optic nerve, which showed minimal and no transduction with AdLacZ.10, respectively, implies diffusion of secreted PEDF to these sites. Incubation of primary antibody with PEDF eliminated the staining, indicating specificity for PEDF (Figure 1n and g ). Four days after injection of an adenoviral vector coding for the extracellular portion of vascular endothelial growth factor receptor-1, there was no staining for PEDF in the retina or periocular tissue (Figure 1o and r) .
In several mice, ocular tissues were carefully dissected from ipsilateral and contralateral orbits and eyes 4 days after periocular injection of 5 Â 10 9 particles of Ad-PEDF.11. ELISAs for PEDF showed significantly higher levels of PEDF in orbital tissue, sclera, choroid, retina, and anterior segment from the injected side compared to the contralateral side (Figure 2 ). Levels of PEDF were particularly high in sclera, choroid, and anterior segment. The relatively low PEDF level measured in orbital tissue is likely because transduction is limited to a relatively small percentage of cells within the orbit, because the lacrimal gland occupies a substantial volume and is not transduced. The elevated levels in the retina corroborate the immunohistochemical findings and indicate that PEDF is able to pass through the choroid and outer blood-retinal barrier and enter the retina.
Recombinant PEDF injected periocularly enters into the retina
The demonstration of intraocular PEDF after periocular injection of AdPEDF.11 suggests that it may also be possible to deliver PEDF to the eye by periocular injection of PEDF protein. To test this, mice were given a periocular injection of 5 ml containing 3 mg of recombinant PEDF and euthanized at 2, 6, or 24 h after injection. Immunohistochemical staining showed a strong signal for PEDF in the periocular tissue and sclera at 2, 6, and 24 h after injection (Figure 3a-c) . There was little staining for PEDF in the retina 2 or 6 h after injection, but by 24 h after injection, there was an unequivocal signal for PEDF. This signal was competed out by preincubation of the primary antibody with PEDF ( Figure 3d ). Eyes not given a periocular injection showed no staining for PEDF (Figure 3e ). An eye given a periocular injection of AdPEDF.11 was used as a positive control and showed staining for PEDF in periocular tissue and faint staining in the retina (Figure 3f ).
Periocular injection of AdPEDF.11 suppresses choroidal neovascularization C57BL/6 mice had laser-induced rupture of Bruch's membrane at three locations in each eye and then received a periocular injection of 5 Â 10 9 or 1 Â 10 9 particles of AdPEDF.11 on the right side and a periocular injection of 5 Â 10 9 particles of AdNull.11 or no injection on the left side. Eyes that had not received any periocular injection (n¼32 eyes, 76 rupture sites) showed large areas of choroidal neovascularization at Bruch's membrane rupture sites (Figure 4a and b) . The size and appearance of choroidal neovascularization was very similar in eyes Figure 1 Reporter gene or PEDF expression after periocular injection of adenoviral vectors. In all, 13 adult C57BL/6 mice were given a 3 ml injection containing 5 Â 10 9 particles of AdLacZ.10 in one eye and killed 1 (n¼4), 4 (n¼4), or 14 days (n¼5) after injection. Periocular and ocular expression of LacZ was assessed on day 4 and expression was evaluated in the liver on days 1, 4, and 14. (a) Orbital sections through regions adjacent to the site of injection showed strong staining for LacZ in the rectus muscle (asterisk), connective tissue, and fat. The episclera was often stained all the way around the globe (arrow). (b) High magnification view of the left side of the section from (a) shows faint LacZ staining in the retina (arrow head), indicating that a small amount of virus was able to pass through the sclera and transfect some retinal cells. There is strong staining in the episclera (arrow) and rectus muscle (above the asterisk). Recombinant PEDF protein diffuses into the eye from the periocular space. Adult C57BL/6 mice were given a periocular injection of 5 ml containing 3 mg of recombinant PEDF in one eye and euthanized 2, 6, or 24 h after injection. Ocular frozen sections were immunohistochemically stained for PEDF. Red reaction product demonstrates high levels of PEDF in the orbit and sclera 2 (a), 6 (b), or 24 h (c) after injection. There is little staining for PEDF in the retina 2 or 6 h after injection, but there is unequivocal staining in the retina 24 h after injection (c). Incubation of primary antibody with PEDF eliminated all but faint background staining in the episclera (d). Staining for PEDF in control, uninjected eyes showed only faint background (e). A section from a Balb/C mouse given a periocular injection of 5 Â 10 9 particles of AdPEDF.11 showed red reaction product in the orbit and sclera and faint staining in the retina.
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P Gehlbach et al that received a periocular injection of 5 Â 10 9 particles of AdNull.11 (n¼17 eyes, 34 rupture sites; Figure 4c and d) . In contrast, eyes that received a periocular injection of 1 Â 10 9 (n¼17 eyes, 34 rupture sites; Figure 4e and f) or 5 Â 10 9 (n¼33 eyes, 78 rupture sites; Figure 4g and h) particles of AdPEDF.11 had small areas of choroidal neovascularization. This impression was confirmed by image analysis, which showed that periocular injection of 1 Â 10 9 or 5 Â 10 9 particles of AdPEDF.11 resulted in significantly smaller areas of choroidal neovascularization than periocular injection of 5 Â 10 9 particles of AdNull.11 (Figure 5i ). An overall treatment effect was identified by ANOVA (P¼0.0016). An adjustment for multiple comparisons using Tukey's test or the Bonferroni test showed significant differences (Po0.05) for Null vector versus 5 Â 10 9 AdPEDF.11 or Null vector versus 1 Â 10 9 AdPEDF.11. Results from the GLM procedure with the Dunnett's Test were consistent with the ANOVA test.
Periocular injection of AdPEDF.11 does not significantly reduce retinal neovascularization due to ischemic retinopathy
In mice with ischemic retinopathy, periocular injection of 5 Â 10 9 particles of AdPEDF.11 did not cause significant reduction of retinal neovascularization compared to eyes that did not receive an injection or those that received a periocular injection of 5 Â 10 9 particles of AdNull.11 ( Figure 5 ). ANOVA showed no evidence of a treatment effect.
Discussion
Gene therapy provides a novel way to achieve sustained local delivery of therapeutic proteins to the eye. However, the safety and feasibility of intraocular injections of vectors in humans are unknown. Intraocular injections themselves carry a low risk of infection, retinal detachment, hemorrhage, and cataract, but until repeated intraocular injections of antiangiogenic agents are examined in the context of clinical trials, the magnitude of the risks will not be known. Vector-related toxicity may not be as much of a problem as once thought, even for adenovirus, 33 but the consequences of any toxicity are likely to be more significant after intraocular injection compared to injections outside the eye, because damaged retinal neurons cannot be replaced. Also, highly specialized retinal neurons may be more easily damaged from excessive production of transgenes compared to connective tissue cells. 24, 25 In this study, we tested the hypothesis that therapeutic proteins can be delivered to the retina and choroid after periocular injection of vector. Periocular injection of AdLacZ.10 showed that connective tissue cells in the orbit were strongly transduced. Episcleral tissue was particularly prone to transduction and often showed LacZ expression in areas remote from the injection site extending all around the globe, suggesting that virus may spread well in the sub-Tenon's space and/or Ad vectors have a strong tropism for episclera. Periocular injection of AdPEDF.11 resulted in significantly increased levels of PEDF in the retina, choroid, sclera, anterior segment, and orbital connective tissue compared to the same structures from the contralateral side. Immunohistochemistry showed staining for PEDF in the ipsilateral, but not the contralateral retina. Rare transduced cells were seen in the liver, indicating that a small amount of vector entered the circulation, but PEDF levels in the serum were at the limit of detection and were not different from serum levels in uninjected mice. This suggests that the exposure of vector and transgene to extraocular tissues is small and that the transgene is provided to the retina and choroid primarily by local diffusion and not through the circulation. Therefore, periocular cell-derived-PEDF, a 50 kDa protein, is able to pass through mouse sclera and gain access to the choroid and retina. Furthermore, the levels of intraocular PEDF attained after periocular injection of AdPEDF.11 are sufficient to suppress choroidal neovascularization strongly. Additional studies are needed to determine if PEDF can diffuse through sclera in larger animals and, if so, there is a good chance that choroidal diseases may be treated by periocular injection of vectors encoding secreted proteins of 50 kDa or less. However, it should be noted that the orbit is not an immune privileged space and, while adenovirus has been used for proof of concept, investigations with other vectors that do not incite an immune response will be useful.
Periocular injection of AdPEDF.11 did not cause inhibition of retinal neovascularization in mice with ischemic retinopathy. Although levels of PEDF in the retina were elevated, they were roughly 10-fold lower than levels of PEDF in the choroid. The level of PEDF in the retina may have been below a critical threshold required for an antiangiogenic effect and hence the lack of effect on retinal neovascularization. Therefore, the prospect for treating retinal diseases with periocular gene transfer is not as good as the prospect for treating choroidal diseases.
In addition to demonstrating that PEDF produced by periocular cells is able to enter the mouse eye and inhibit choroidal neovascularization, we have found that periocular injection of recombinant PEDF also results in diffusion of PEDF through the sclera into the choroid and retina. If this can also be done in larger animals, then any way of achieving high periocular levels of appropriatesized therapeutic proteins may be considered for the treatment of retinal and choroidal diseases. Biodegradable or nondegradable sustained release implants could be sutured to the sclera or injectable formulations for sustained release of proteins could be considered. Alternatively, osmotic pumps could be used to deliver proteins to the periocular space. Using this approach, Ambati et al 34 demonstrated that a 150 kDa protein, an anti-intercellular adhesion molecule-1 monoclonal antibody, was able to penetrate the sclera and inhibit VEGFinduced stimulation of myeloperoxidase activity in the choroid and the retina. If only a very brief exposure of the protein is needed, periocular injection of a protein solution could be done.
If a 50 kDa protein can pass through mouse sclera and achieve therapeutic levels in the choroid and retina, smaller molecules should be able to do so with even greater facility. Proof of principle has been provided for implantation of sustained release devices in the vitreous cavity. 35 Our data suggest that implantation of sustained release devices in the periocular space could be considered as an alternative, and would have the advantages of a lower risk of endophthalmitis and Periocular injection of AdPEDF vectors P Gehlbach et al retinal detachment, and easier retrieval and/or replacement.
Our study raises several questions that should be addressed in the future. What is the upper size limit for proteins for local diffusion into the choroid and retina from the periocular space? Do other characteristics of proteins play a role in their diffusability? In vitro studies have suggested that molecular radius may be a more important determinant than molecular weight and that 150 kDa globular proteins with a molecular radius of 5.23 nm are able to penetrate the sclera. 36 One would predict that proteins that bind to one or more components of the extracellular matrix would have less ability to gain access to the choroid and retina when expressed or released in the periocular space, but this should be tested. Will periocular injection of other vectors that usually result in longer duration transgene expression, such as adeno-associated viral vectors or lentiviral vectors, result in a similar pattern and level of expression and provide long-term treatment for chronic retinal and choroidal diseases with a single injection? We plan to address these questions in future studies.
